This inventor holds 1 USPTO granted patent and 4 published patent applications and 2 EPO patents. Top assignee: Iomx Therapeutics Ag. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Antonio Sorrentino: Innovator in Cancer Research
Introduction
Antonio Sorrentino is an accomplished inventor based in Wuppertal, Germany. He has made significant contributions to the field of cancer research, particularly in understanding the mechanisms of tumor resistance to immune responses. Although he currently holds no granted patents, his work has the potential to lead to groundbreaking therapeutic approaches.
Latest Patent Applications
Antonio Sorrentino's notable patent application is titled "Intracellular Kinase Associated with Resistance Against T-Cell Mediated Cytotoxicity, and Uses Thereof." This invention focuses on the identification of the intracellular kinase calcium/calmodulin-dependent protein kinase 1D (CAMK1D) as a key checkpoint inhibitor in tumor cells. The research highlights how CAMK1D mediates resistance against cytotoxic T lymphocytes (CTL) and offers therapeutic approaches to impair its function. The application discusses various inhibitors of CAMK1D, including nucleic acid or small molecule inhibitors, and their potential use in treating proliferative disorders that exhibit resistance to CTL-mediated immune responses.
Conclusion
Antonio Sorrentino's innovative work in cancer research showcases his dedication to advancing medical science. His research on CAMK1D could pave the way for new treatments for patients facing challenges with current immune checkpoint therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile